Skip to main content
OpenTrials
Completed

NCT Number: NCT02579681

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

The primary objective(s) of the study are to assess the BG00012 (dimethyl fumarate) treatment effect on cognition over 2 year period in RRMS patients. The secondary objectives of this study are to further assess BG00012 treatment effect on cognition, predictors of cognitive impairment, clinical efficacy, and patient reported outcomes (PRO): depression, fatigue, quality of life, and work and social life activity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis, Relapsing-Remitting Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Multiple Sclerosis Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research site, Bari, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Must have a confirmed diagnosis of RRMS according to McDonald criteria (Polman, Reingold et al. 2005).
  • Must have a baseline EDSS between 0.0 and 5.0, inclusive.
  • Must have experienced at least 1 relapse within the 12 months prior to randomization, with a prior brain MRI demonstrating lesion(s) consistent with MS, or show evidence of gadolinium-enhancing lesion(s) of the brain on an MRI performed within the 6 weeks prior to randomization.

Key Exclusion Criteria:

Candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of screening:

  • Primary progressive, secondary progressive, or progressive relapsing MS, as defined by Lublin and Reingold (Lublin and Reingold 1996)
  • Severe depression (MADRS score >34) (Montgomery and Asberg 1979)
  • History of malignancy (except basal cell carcinoma that has been completely excised prior to study enrollment)
  • An MS relapse that has occurred within the 30 days prior to inclusion AND/OR the participant has not stabilized from a previous relapse prior to inclusion.

Treatment and study plan

dimethyl fumarate

Drug

dimethyl fumarate administered as per the arm description

Other names: Tecfidera, DMF, BG00012

Primary outcomes

  1. Proportion of patients with worsening in cognitive improvement over 2 years.

    Time frame: Up to 2 years

    As measured by at least 2 standard deviation (SD) below Italian normative data of the Rao's Brief Repeatable Battery of Neuropsychological Tests (BRB) and a 100-item version of the Stroop Test. The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) is a sensitive measure of cognitive impairment in multiple sclerosis (MS) patients. The Stroop Test is a test used to measure a person's sustained attention for word reading and color naming with and without interference.

Secondary outcomes

  1. Change in cognitive impairment index score (CII) over two years

    Time frame: Up to 2 years

    An individual cognitive change index will be measured by calculating changes on the cognitive impairment index (CII) for each participant between year 0 and year 1, and year 0 and year 2. The CII is an individual cognitive change index aimed at providing a more precise assessment of the amount and direction of cognitive changes over time.

  2. Annualized relapse rate at year 1.

    Time frame: Up to one year

  3. Annualized relapse rate at year 2.

    Time frame: Up to 2 years

  4. Time to relapse over 2 years.

    Time frame: 2 years

  5. Proportion of patients with 6-month sustained progression of disability as measured by at least a 1.0 point increase from a baseline EDSS>1.0 or at least a 1.5 point increase from a baseline EDSS=0).

    Time frame: Up to 2 years

    The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. Each functional system is scored on a scale of 0 (no disability) to 5 or 6 (more severe disability). EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation.

  6. Assessment of baseline demographic, disease characteristics and related patient reported outcomes that predict CI at two years.

    Time frame: Up to 2 years

    Demographics may include age and gender, disease characteristics may include year of diagnosis and disability and PRO may include fatigue and depression at the time of initiation of BG00012.

  7. Change from baseline in a self rating version of the Montgomery and Asberg Depression Rating Scale (MADRS)

    Time frame: 2 years

    The MADRS instrument has nine questions, with an overall score ranging from 0 to 27 points

  8. Change from baseline in fatigue as measured by the Modified Fatigue Impact Scale (MFIS)

    Time frame: 2 years

    The MFIS is a modified form of the Fatigue Impact Scale based on items derived from interviews with MS patients concerning how fatigue impacts their lives. This instrument provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning. The full-length MFIS consists of 21 items

  9. Change from baseline in Quality of life (QOL) as measured by the EQ-5D Health Survey

    Time frame: 2 years

    The EQ-5D is a widely-used survey instrument for measuring economic preferences for health states. It is a self-administered questionnaire consisting of 5 sets of 3 questions pertaining to specific health states (i.e., mobility, self-care, pain, usual activities, anxiety).

  10. Change from baseline in the Environmental Status Scale (ESS)

    Time frame: 2 years

    The Environmental Status Scale (ESS) is used to quickly evaluate a patient for handicap. It was derived from a measure of socio-economic status. It consists of seven parameters: (1) actual work status, (2) financial and economic status, (3) personal residence or home, (4) personal assistance required, (5) transportation, (6) community services, (7) social activity. Each parameter has a single score from minimum 0 to maximum 5. ESS score is the sum of the points for all 7 parameters: minimum score: 0; maximum score: 35. The higher the score the greater the handicap.

Sponsors and collaborators

Lead sponsor

Biogen

Industry

Registry information

Official study title

Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012

Acronym: StarTec

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Oct 20, 2015
Registry last updated
Apr 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.